STAA Share Price Performance
US$28.00
-0.55 (-1.93%)
0.9% overvalued intrinsic discount
US$27.75
Fair Value
Price US$28.00
AnalystHighTarget US$27.75
AnalystLowTarget US$15.25
AnalystConsensusTarget US$25.88
Fair ValueUS$28.00
Share Pricen/a
STAAR Surgical Company Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
STAA Community Narratives
AN
Fair Value US$28 0% overvalued intrinsic discount
Growing Myopia And Aging Population Will Expand Vision Correction Opportunities
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$16 75.0% overvalued intrinsic discount
Geopolitical Tensions And Regulatory Pressures Will Depress Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$25.88 8.2% overvalued intrinsic discount
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Key Takeaways Anticipated recovery in China driven by potential demand rebound and new product launch could boost revenue and ASPs. Strong financial position with no debt enables investment in selective growth initiatives and optimization of cash flow management. The company faces challenges from weak macroeconomic conditions in China, reliance on a single distributor model, competitive pressures, and potential impacts from cost-cutting measures.Read more
2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$25.88
8.2% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
17.15% p.a.
Profit Margin
1.48%
Future PE
301.88x
Share price in 2028
US$32.25
Growing Myopia And Aging Population Will Expand Vision Correction Opportunities
Key Takeaways Strong demand drivers and strategic innovation position the company for sustained growth and expanding market share, especially as clinical adoption and patient awareness increase. Manufacturing expansion and targeted market development in Asia-Pacific are expected to drive higher profits, improved margins, and operational efficiency.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$28
0% overvalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
26.05% p.a.
Profit Margin
29.97%
Future PE
12.9x
Share price in 2028
US$34.44
Geopolitical Tensions And Regulatory Pressures Will Depress Margins
Key Takeaways Over-reliance on a narrow product portfolio and vulnerability to technological disruption pose significant concentration and innovation risks. Mounting regulatory, geopolitical, and competitive pressures threaten margins, pricing power, and expansion into new global markets.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$16
75.0% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
13.1% p.a.
Profit Margin
12.32%
Future PE
24.8x
Share price in 2028
US$19.68
Recently Updated Narratives
AN
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Fair Value: US$25.88 8.2% overvalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Geopolitical Tensions And Regulatory Pressures Will Depress Margins
Fair Value: US$16 75.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Growing Myopia And Aging Population Will Expand Vision Correction Opportunities
Fair Value: US$28 0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
STAAR Surgical Company Key Details
About STAA
- Founded
- 1982
- Employees
- 1157
- CEO
- WebsiteView website
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
